Medallion Wealth Advisors’s Pacific Biosciences PACB Stock Holding History

Medallion Wealth Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$132	Hold	100	–	–	﹤0.01%	1107
2025 Q4	$187	Hold	100	–	–	﹤0.01%	1097
2025 Q3	$128	Hold	100	–	–	﹤0.01%	1087
2025 Q2	$129	Hold	100	–	–	﹤0.01%	1076
2025 Q1	$113	Hold	100	–	–	﹤0.01%	1054
2024 Q4	$183	Buy	+100	New	+$195	﹤0.01%	987

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Medallion Wealth Advisors's PACB Position: Q1 2026 in Review

Medallion Wealth Advisors held its Pacific Biosciences (PACB) position steady in Q1 2026 at 100 shares worth $132. The position accounts for ﹤0.01% of the portfolio, ranked #1107.

Medallion Wealth Advisors first reported a position in PACB in Q4 2024 and has held it in 6 quarters since. The position peaked at $187 in Q4 2025. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Medallion Wealth Advisors held 100 shares of Pacific Biosciences worth $132 as of Q1 2026.
Medallion Wealth Advisors left its Pacific Biosciences share count unchanged in Q1 2026.
Pacific Biosciences made up ﹤0.01% of Medallion Wealth Advisors's portfolio in Q1 2026, its #1107 holding.
Medallion Wealth Advisors first reported a position in Pacific Biosciences in Q4 2024 and has held it in 6 quarters since.
Medallion Wealth Advisors's Pacific Biosciences position peaked at $187 in Q4 2025.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Medallion Wealth Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.